Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naïve to nevirapine by using stochastic simulations and a mathematical model

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 10230-10240

  Gadhamsetty, Saikrishna ^a   Dixit, Narendra M ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; RETROVIRUS; STOCHASTIC MODEL; VIROGENESIS; VIRUS GENOME; VIRUS STRAIN; BIOLOGICAL MODEL; DRUG EFFECTS; FEMALE; GENETICS; HIV INFECTIONS; HUMAN; MATHEMATICAL PHENOMENA; MOLECULAR EVOLUTION; NEWBORN; PREGNANCY; PREVENTION AND CONTROL; STATISTICS; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENOME, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATHEMATICAL CONCEPTS; MODELS, BIOLOGICAL; NEVIRAPINE; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS; STOCHASTIC PROCESSES;

EID: 77956818983     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01010-10     Document Type: Article

References (65)

1. Achaz, G., S. Palmer, M. Kearney, F. Maldarelli, J. W. Mellors, J. M. Coffin, and J. Wakeley. 2004. A robust measure of HIV-1 population turnover within chronically infected individuals. Mol. Biol. Evol. 21:1902-1912.
2. Arora, P., and N. M. Dixit. 2009. Timing the emergence of resistance to anti-HIV drugs with large genetic barriers. PLoS Comput. Biol. 5:e1000305.
3. Bonhoeffer, S., C. Chappey, N. T. Parkin, J. M. Whitcomb, and C. J. Petropoulos. 2004. Evidence for positive epistasis in HIV-1. Science 306:1547-1550.
4. Chen, B. K., R. T. Gandhi, and D. Baltimore. 1996. CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J. Virol. 70:6044-6053.
5. Chen, H. Y., M. Di Mascio, A. S. Perelson, D. D. Ho, and L. Zhang. 2007. Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 104:19079-19084.
6. Clavel, F., and A. J. Hance. 2004. HIV drug resistance. N. Engl. J. Med. 350:1023-1035.
7. Coffin, J. M. 1995. HIV population-dynamics in-vivo - implications for genetic-variation, pathogenesis, and therapy. Science 267:483-489.
8. Collins, J. A., M. G. Thompson, E. Paintsil, M. Ricketts, J. Gedzior, and L. Alexander. 2004. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J. Virol. 78:603-611.
9. De Cock, K. M., M. G. Fowler, E. Mercier, I. de Vincenzi, J. Saba, E. Hoff, D. J. Alnwick, M. Rogers, and N. Shaffer. 2000. Prevention of mother-tochild HIV transmission in resource-poor countries - translating research into policy and practice. JAMA 283:1175-1182.
10. + cell turnover. Nature 375:194-195.
11. Dimitrov, D. S., R. L. Willey, H. Sato, L. J. Chang, R. Blumenthal, and M. A. Martin. 1993. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67:2182-2190.
12. Dixit, N. M. 2008. Modelling HIV infection dynamics: the role of recombination in the development of drug resistance. Future HIV Ther. 2:375-388.
13. Dixit, N. M., M. Markowitz, D. D. Ho, and A. S. Perelson. 2004. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir. Ther. 9:237-246.
14. Eshleman, S. H., D. R. Hoover, S. Chen, S. E. Hudelson, L. A. Guay, A. Mwatha, S. A. Fiscus, F. Mmiro, P. Musoke, J. B. Jackson, N. Kumwenda, and T. Taha. 2005. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J. Infect. Dis. 192:30-36.
15. Eshleman, S. H., M. Mracna, L. A. Guay, M. Deseyve, S. Cunningham, M. Mirochnick, P. Musoke, T. Fleming, M. G. Fowler, L. M. Mofenson, F. Mmiro, and J. B. Jackson. 2001. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15:1951-1957.
16. Flys, T., D. V. Nissley, C. W. Claasen, D. Jones, C. J. Shi, L. A. Guay, P. Musoke, F. Mmiro, J. N. Strathern, J. B. Jackson, J. R. Eshleman, and S. H. Eshleman. 2005. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J. Infect. Dis. 192:24-29.
17. Flys, T. S., D. Donnell, A. Mwatha, C. Nakabiito, P. Musoke, F. Mmiro, J. B. Jackson, L. A. Guay, and S. H. Eshleman. 2007. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J. Infect. Dis. 195:711-715.
18. Flys, T. S., M. S. McConnell, F. Matovu, J. D. Church, D. Bagenda, L. Khaki, P. Bakaki, M. C. Thigpen, C. Eure, M. G. Fowler, and S. H. Eshleman. 2008. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J. Infect. Dis. 198:465-469.
19. Gao, F., and D. Wang. 2007. Minor-drug-resistant HIV populations and treatment failure. Future Virol. 2:293-302.
20. Haase, A. T., K. Henry, M. Zupancic, G. Sedgewick, R. A. Faust, H. Melroe, W. Cavert, K. Gebhard, K. Staskus, Z. Q. Zhang, P. J. Dailey, H. H. Balfour, A. Erice, and A. S. Perelson. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274:985-989.
21. Hockett, R. D., J. M. Kilby, C. A. Derdeyn, M. S. Saag, M. Sillers, K. Squires, S. Chiz, M. A. Nowak, G. M. Shaw, and R. P. Bucy. 1999. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J. Exp. Med. 189:1545-1554.
22. Jackson, J. B., P. Musoke, T. Fleming, L. A. Guay, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, M. Owor, C. Ducar, M. Deseyve, A. Mwatha, L. Emel, C. Duefield, M. Mirochnick, M. G. Fowler, L. Mofenson, P. Miotti, M. Gigliotti, D. Bray, and F. Mmiro. 2003. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868.
23. Johnson, J. A., J. F. Li, L. Morris, N. Martinson, G. Gray, J. McIntyre, and W. Heneine. 2005. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192:16-23.
24. Johnson, J. A., J. F. Li, X. Wei, J. Lipscomb, D. Irlbeck, C. Craig, A. Smith, D. E. Bennett, M. Monsour, P. Sandstrom, E. R. Lanier, and W. Heneine. 2008. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5:1112-1122.
25. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1: spring 2008. Top. HIV Med. 16:62-68.
26. Josefsson, L., J. Brannstrom, B. Makilato, F. Maldarelli, M. Kearney, W. Shao, J. Mellors, J. Albert, J. Coffin, and S. Palmer. 2010. Analysis of HIV DNA molecules in single infected cells from recently and chronically infected patients, abstr. 289, 17th Conf. Retrovir. Opportunistic Infect., San Francisco, CA.
27. Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, and M. Lallemant. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240.
28. Jung, A., R. Maier, J. P. Vartanian, G. Bocharov, V. Jung, U. Fischer, E. Meese, S. Wain-Hobson, and A. Meyerhans. 2002. Multiply infected spleen cells in HIV patients. Nature 418:144.
29. Keele, B. F., E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. X. Sun, T. Grayson, S. Y. Wang, H. Li, X. P. Wei, C. L. Jiang, J. L. Kirchherr, F. Gao, J. A. Anderson, L. H. Ping, R. Swanstrom, G. D. Tomaras, W. A. Blattner, P. A. Goepfert, J. M. Kilby, M. S. Saag, E. L. Delwart, M. P. Busch, M. S. Cohen, D. C. Montefiori, B. F. Haynes, B. Gaschen, G. S. Athreya, H. Y. Lee, N. Wood, C. Seoighe, A. S. Perelson, T. Bhattacharya, B. T. Korber, B. H. Hahn, and G. M. Shaw. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557.
30. Kouyos, R. D., C. L. Althaus, and S. Bonhoeffer. 2006. Stochastic or deterministic: what is the effective population size of HIV-1? Trends Microbiol. 14:507-511.
31. Lapadula, G., I. Izzo, F. Gargiulo, G. Paraninfo, F. Castelnuovo, E. Quiros-Roldan, G. Cologni, F. Ceresoli, N. Manca, G. Carosi, and C. Torti. 2008. Updated prevalence of genotypic resistance among HIV-1 positive patients naive to antiretroviral therapy: a single center analysis. J. Med. Virol. 80:747-753.
32. Levy, D. N., G. M. Aldrovandi, O. Kutsch, and G. M. Shaw. 2004. Dynamics of HIV-1 recombination in its natural target cells. Proc. Natl. Acad. Sci. U. S. A. 101:4204-4209.
33. Lockman, S., R. L. Shapiro, L. M. Smeaton, C. Wester, I. Thior, L. Stevens, F. Chand, J. Makhema, C. Moffat, A. Asmelash, P. Ndase, P. Arimi, E. van Widenfelt, L. Mazhani, V. Novitsky, S. Lagakos, and M. Essex. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356:135-147.
34. Loubser, S., P. Balfe, G. Sherman, S. Hammer, L. Kuhn, and L. Morris. 2006. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 20:995-1002.
35. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human-immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
36. Martinson, N. A., D. K. Ekouevi, F. Dabis, L. Morris, P. Lupodwana, B. Tonwe-Gold, P. Dhlamini, R. Becquet, J. G. Steyn, V. Leroy, I. Viho, G. E. Gray, and J. A. McIntyre. 2007. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. J. Acquir. Immun. Defic. Syndr. 45:206-209.
37. Martinson, N. A., L. Morris, G. Gray, D. Moodley, V. Pillay, S. Cohen, P. Dhlamini, A. Puren, S. Bhayroo, J. Steyn, and J. A. McIntyre. 2007. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J. Acquir. Immun. Defic. Syndr. 44:148-153.
38. McIntyre, J., and N. Martinson. 2007. Prophylactic regimens to prevent mother-to-child transmission of HIV and their effect on future therapy. Therapy 4:797-805.
39. Metzner, K. J., S. G. Giulieri, S. A. Knoepfel, P. Rauch, P. Burgisser, S. Yerly, H. F. Gunthard, and M. Cavassini. 2009. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin. Infect. Dis. 48:239-247.
40. Nijhuis, M., C. A. B. Boucher, P. Schipper, T. Leitner, R. Schuurman, and J. Albert. 1998. Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. U. S. A. 95:14441-14446.
41. Novak, R. M., L. Chen, R. D. MacArthur, J. D. Baxter, K. H. Hullsiek, G. Peng, Y. Xiang, C. Henely, B. Schmetter, J. Uy, M. van den Berg-Wolf, and M. Kozal. 2005. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin. Infect. Dis. 40:468-474.
42. Paintsil, E., A. Margolis, J. A. Collins, and L. Alexander. 2006. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance. J. Med. Virol. 78:425-430.
43. Palmer, S., V. Boltz, F. Maldarelli, M. Kearney, E. K. Halvas, D. Rock, J. Falloon, R. T. Davey, Jr., R. L. Dewar, J. A. Metcalf, J. W. Mellors, and J. M. Coffin. 2006. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 20:701-710.
44. Palmer, S., V. Boltz, N. Martinson, F. Maldarelli, G. Gray, J. McIntyre, J. Mellors, L. Morris, and J. Coffin. 2006. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc. Natl. Acad. Sci. U. S. A. 103:7094-7099.
45. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K. C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High-levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
46. Piguet, V., F. Gu, M. Foti, N. Demaurex, J. Gruenberg, J. L. Carpentier, and D. Trono. 1999. Nef-induced CD4 degradation: a diacidic-based motif in Nef functions as a lysosomal targeting signal through the binding of beta-COP in endosomes. Cell 97:63-73. (Pubitemid 29165890)
47. Rhodes, T., H. Wargo, and W.-S. Hu. 2003. High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication. J. Virol. 77:11193-11200. (Pubitemid 37204309)
48. Ribeiro, R. M., S. Bonhoeffer, and M. A. Nowak. 1998. The frequency of resistant mutant virus before antiviral therapy. AIDS 12:461-465.
49. Ribeiro, R. M., L. Qin, L. L. Chavez, D. Li, S. G. Self, and A. S. Perelson. 2010. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J. Virol. 84:6096-6102.
50. Rodrigo, A. G., E. G. Shpaer, E. L. Delwart, A. K. N. Iversen, M. V. Gallo, J. Brojatsch, M. S. Hirsch, B. D. Walker, and J. I. Mullins. 1999. Coalescent estimates of HIV-1 generation time in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:2187-2191.
51. Rouzine, I., E. Gubankova, M. Kearney, S. Palmer, F. Maldarelli, and J. Coffin. 2008. Estimate of the frequency of HIV-1 co-infection in vivo, abstr. 345. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.
52. Rouzine, I. M., and J. M. Coffin. 1999. Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc. Natl. Acad. Sci. U. S. A. 96:10758-10763.
53. Seo, T. K., J. L. Thorne, M. Hasegawa, and H. Kishino. 2002. Estimation of effective population size of HIV-1 within a host: a pseudomaximum-likelihood approach. Genetics 160:1283-1293.
54. Shriner, D., R. Shankarappa, M. A. Jensen, D. C. Nickle, J. E. Mittler, J. B. Margolick, and J. I. Mullins. 2004. Influence of random genetic drift on human immunodeficiency virus type I env evolution during chronic infection. Genetics 166:1155-1164.
55. Siliciano, J. D., J. Kajdas, D. Finzi, T. C. Quinn, K. Chadwick, J. B. Margolick, C. Kovacs, S. J. Gange, and R. F. Siliciano. 2003. Long-term follow- up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat. Med. 9:727-728.
56. Simen, B. B., J. F. Simons, K. H. Hullsiek, R. M. Novak, R. D. MacArthur, J. D. Baxter, C. L. Huang, C. Lubeski, G. S. Turenchalk, M. S. Braverman, B. Desany, J. M. Rothberg, M. Egholm, and M. J. Kozal. 2009. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199:693-701.
57. Simon, V., D. D. Ho, and Q. A. Karim. 2006. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368:489-504.
58. Speirs, C., E. van Nimwegen, D. Bolton, M. Zavolan, M. Duvall, S. Angleman, R. Siegel, A. S. Perelson, and M. J. Lenardo. 2005. Analysis of human immunodeficiency virus cytopathicity by using a new method for quantitating viral dynamics in cell culture. J. Virol. 79:4025-4032.
59. Stafford, M. A., L. Corey, Y. Z. Cao, E. S. Daar, D. D. Ho, and A. S. Perelson. 2000. Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 203:285-301.
60. Stringer, J. S. A., M. S. McConnell, J. Kiarie, O. Bolu, T. Anekthananon, T. Jariyasethpong, D. Potter, W. Mutsotso, C. B. Borkowf, D. Mbori-Ngacha, P. Muiruri, J. O. Ong'ech, I. Zulu, L. Njobvu, B. Jetsawang, S. Pathak, M. Bulterys, N. Shaffer, and P. J. Weidle. 2010. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. PLoS Med. 7:e1000233.
61. Suryavanshi, G. W., and N. M. Dixit. 2007. Emergence of recombinant forms of HIV: dynamics and scaling. PLoS Comput. Biol. 3:2003-2010.
62. UNAIDS. 2009. AIDS epidemic update: December 2009. UNAIDS, Geneva, Switzerland. http://data.unaids.org/pub/Report/2009/JC1700-Epi-Update-en.pdf.
63. Vijay, N. N. V., Vasantika, R. Ajmani, A. S. Perelson, and N. M. Dixit. 2008. Recombination increases human immunodeficiency virus fitness, but not necessarily diversity. J. Gen. Virol. 89:1467-1477.
64. Wind-Rotolo, M., C. Durand, L. Cranmer, A. Reid, N. Martinson, M. Doherty, B. L. Jilek, J. Kagaayi, A. Kizza, V. Pillay, O. Laeyendecker, S. J. Reynolds, S. H. Eshleman, B. Lau, S. C. Ray, J. D. Siliciano, T. C. Quinn, and R. F. Siliciano. 2009. Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J. Infect. Dis. 199:1301-1309.
65. Wu, H., Y. Huang, C. Dykes, D. Liu, J. Ma, A. S. Perelson, and L. M. Demeter. 2006. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J. Virol. 80:2380-2389.